

Phathom[®]

PHARMACEUTICALS

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

October 25, 2023

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November:

Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference in New York, NY

Date: Tuesday, November 7, 2023

Live Webcast: 2:30 p.m. ET

Management to participate in one-on-one meetings throughout the conference

Jefferies London Healthcare Conference in London, England

Date: Tuesday, November 14, 2023

Live Webcast: 10:30 a.m. ET

Management to participate in one-on-one meetings throughout the conference

Stifel 2023 Healthcare Conference in New York, NY

Date: Wednesday, November 15, 2023

Live Webcast: 2:25 p.m. ET

Management to participate in one-on-one meetings throughout the conference

Craig-Hallum 14th Annual Alpha Select Conference in New York, NY

Date: Thursday, November 16, 2023

Management to participate in one-on-one meetings throughout the conference

Evercore ISI 6th Annual HealthCONx Conference in Miami, FL

Date: Wednesday, November 29, 2023

Live Webcast: 4:15 p.m. ET

Management to participate in one-on-one meetings throughout the conference

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. Recordings will be available for 90 days following the conclusion of each meeting.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company's website at www.phathompharma.com and follow the Company on [LinkedIn](#) and [Twitter](#).

MEDIA CONTACT

Nick Benedetto

1-877-742-8466

media@phathompharma.com

INVESTOR CONTACT

Eric Sciorilli

1-877-742-8466

ir@phathompharma.com

